Clinical trials: Non-diabetic Chronic Kidney Disease
Non-diabetic Chronic Kidney Disease, Atherosclerosis
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.
- Trial name
- NCT01701830
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kocaeli Derince Education and Research Hospital
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Inflammation, Chronic Kidney Disease
Role of Prohepcidin in Uremic Patients
The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients.
- Trial name
- NCT01735773
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Haseki Training and Research Hospital
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Renal Insufficiency, Chronic
The Incretin Effect in Patients With Kidney Impairment
The current study explores the incretin effect; a central mechanism of sugar metabolism. People with type 2 diabetes have a markedly reduced incretin effect, while the incretin effect never has been studied in patients with…
- Trial name
- UREMINC (NCT01327378)
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen